SOPH Market Analysis

Overview

Fundamentals

P/E ratio
EPS (TTM)$-1.180.0% YoY
Profit margin-99.7%HEALTHCARE
Market cap$377.3MSmall cap

Wall Street coverage

$8.00median target· current $4.70 (+70.2%)4 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E
PEG ratio
P/B
8.25
P/S (TTM)
4.65
EV/EBITDA
-0.30

Profitability & growth

ROE (TTM)
-123.3%
Operating margin
-79.7%
Revenue growth YoY
22.0%
Dividend yield
Beta
0.98
Last earnings
May 5, 2026 · Estimate $-0.24 · Reported $-0.19
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Sophia Genetics SA

Sophia Genetics SA (SOPH) is a leading innovator in data-driven medicine, specializing in advanced genomic and clinical data analytics aimed at improving patient outcomes. By leveraging state-of-the-art machine learning technologies, the company offers an integrated platform that empowers healthcare providers to decipher intricate genomic data, thereby enabling personalized treatment approaches in areas such as oncology, rare diseases, and hereditary conditions. With a strong global presence and strategic collaborations with key healthcare organizations, Sophia Genetics is poised to reshape…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
LA PIECE 12, ROLLE, SWITZERLAND
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$377.3M
Shares outstanding$71.8M
52W high$5.70
52W low$2.59

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer